Page last updated: 2024-11-08

galactosucrose

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

galactosucrose: a non-digestible trisaccharide produced from lactose and sucrose by beta-fructofuranosidase [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID174626
SCHEMBL ID6446665
MeSH IDM0217971

Synonyms (15)

Synonym
galactosucrose
(2s,3r,4s,5r,6r)-2-[(2r,3s,4r,5r,6r)-6-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol
alpha-d-glucopyranoside, beta-d-fructofuranosyl o-beta-d-galactopyranosyl-(1-4)-
beta-d-fructofuranosyl o-beta-d-galactopyranosyl-(1-4)-alpha-d-glucopyranoside
4(g)-beta-d-galactosylsucrose
galactosylsucrose
lactosucrose
87419-56-5
o-beta-d-galactopyranosyl-(1-4)-o-alpha-d-glucopyranosyl-(1-2)-beta-d-fructofuranoside
SCHEMBL6446665
4-o-beta-d-galactopyranosyl-d-sucrose, min. 97%
(2s,3r,4s,5r,6r)-2-((2r,3s,4r,5r,6r)-6-((2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)tetrahydrofuran-2-yloxy)-4,5-dihydroxy-2-(hydroxymethyl)tetrahydro-2h-pyran-3-yloxy)-6-(hydroxymethyl)tetrahydro-2h-pyran-3,4,5-triol
FVVCFHXLWDDRHG-UPLOTWCNSA-N
(2s,3r,4s,5r,6r)-2-(((2r,3s,4r,5r,6r)-6-(((2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)tetrahydrofuran-2-yl)oxy)-4,5-dihydroxy-2-(hydroxymethyl)tetrahydro-2h-pyran-3-yl)oxy)-6-(hydroxymethyl)tetrahydro-2h-pyran-3,4,5-triol
|a-d-fructofuranosyl o-|a-d-galactopyranosyl-(1 inverted exclamation marku4)-|a-d-glucopyranoside

Research Excerpts

Compound-Compound Interactions

ExcerptReferenceRelevance
" In our study, the effects of several polysaccharides such as alginate, κ-carrageenan, locust bean gum, gellan gum, xanthan gum and their combination with various prebiotic components (resistant starch, lactulose, lactosucrose) on encapsulation of probiotic Lactobacillus casei 01 strain were studied."( Effects of various polysaccharides (alginate, carrageenan, gums, chitosan) and their combination with prebiotic saccharides (resistant starch, lactosucrose, lactulose) on the encapsulation of probiotic bacteria Lactobacillus casei 01 strain.
Antal, O; Bujna, E; Gupta, VK; Juhász, R; Kun, S; Ladányi, M; Nguyen, QD; Sudheer, S; Szécsi, A; Ta, LP, 2021
)
0.62

Dosage Studied

ExcerptRelevanceReference
" They were given glutamine three times daily at a dosage of 9 g/day."( Effects of two different glutamine-containing enteral supplements on stool frequency and density in elderly patients recovering from acute critical illness.
Fushimi, N; Hachiya, H; Ito, S; Mori, A; Ohashi, N; Shibuya, T; Yamada, M, 2017
)
0.46
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (37)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (2.70)18.7374
1990's6 (16.22)18.2507
2000's14 (37.84)29.6817
2010's11 (29.73)24.3611
2020's5 (13.51)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.57

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.57 (24.57)
Research Supply Index3.71 (2.92)
Research Growth Index5.28 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.57)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (8.11%)5.53%
Reviews2 (5.41%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other32 (86.49%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]